Approval · Notice of Compliance 16509 · 2015
TEVETEN: Notice of Compliance 16509
Issued January 7, 2015
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16509
- Date
- January 7, 2015
- Company
- BGP Pharma ULCEtobicoke, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Transfer of drug identification numbers
- Therapeutic class
- Angiotensin II receptorl (at1) antagonist
Products in this notice
Medicinal ingredients
- EPROSARTAN MESYLATE 400 MG per TAB
- EPROSARTAN MESYLATE 600 MG per TAB